Amivantamab

In this video, Xiuning Le, MD, PhD, discusses how the definition of EGFR-mutated lung cancer has expanded in recent years.

In this video, Xiuning Le, MD, PhD, discusses how she approaches putting together a treatment plan for a patient with EGFR-mutated lung cancer.

In this video, Xiuning Le, MD, PhD, discusses some of the latest developments in the study and treatment of EGFR-mutated lung cancer.

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, discusses the changing treatment landscape in EGFR-mutated lung cancer.

Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.

In this edition, FDA approves Rybrevant for advanced lung cancer, screening orders in eligible patients higher with digital health program and more.

The FDA approved amivantamab-vmjw in combination with standard chemotherapy for the treatment of certain adults with non-small cell lung cancer, according to the agent’s manufacturer.

The FDA approved amivantamab-vmjw plus lazertinib as first-line treatment for certain adults with non-small cell lung cancer.